Loading clinical trials...
Loading clinical trials...
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Liverpool Hospital
Liverpool, New South Wales, Australia
North West Cancer Centre
North Tamworth, New South Wales, Australia
St Vincent's Hospital Sydney
Sydney, New South Wales, Australia
Mater Hospital Sydney
Sydney, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Adelaide Oncology and Haematology, Calvary Central Districts Hospital
Elizabeth Vale, South Australia, Australia
Icon Cancer Centre - Hobart
Hobart, Tasmania, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Last Updated
December 16, 2024
Abemaciclib
DRUG
Lead Sponsor
Eli Lilly and Company
NCT06625775
NCT06649331
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions